Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research note published on Friday morning,Benzinga reports. They currently have a $6.00 target price on the biopharmaceutical company’s stock.

A number of other brokerages have also recently weighed in on ESPR. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research report on Thursday. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Esperion Therapeutics Stock Performance

Esperion Therapeutics stock opened at $2.25 on Friday. Esperion Therapeutics has a twelve month low of $1.58 and a twelve month high of $3.94. The firm has a market cap of $443.34 million, a PE ratio of -3.52 and a beta of 1.01. The firm’s 50 day moving average price is $2.39 and its two-hundred day moving average price is $2.22.

Hedge Funds Weigh In On Esperion Therapeutics

A number of institutional investors have recently made changes to their positions in ESPR. Wasatch Advisors LP boosted its stake in Esperion Therapeutics by 38.4% during the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after purchasing an additional 6,483,070 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after buying an additional 171,609 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Esperion Therapeutics by 94.2% in the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock valued at $9,554,000 after acquiring an additional 2,087,635 shares during the period. State Street Corp grew its stake in shares of Esperion Therapeutics by 2.7% in the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock worth $6,360,000 after acquiring an additional 99,802 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in Esperion Therapeutics by 71.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock worth $1,174,000 after acquiring an additional 295,378 shares during the period. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.